GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tci Gene Inc (ROCO:6879) » Definitions » Piotroski F-Score

Tci Gene (ROCO:6879) Piotroski F-Score : 4 (As of Jun. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Tci Gene Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tci Gene has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Tci Gene's Piotroski F-Score or its related term are showing as below:

ROCO:6879' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 4

During the past 5 years, the highest Piotroski F-Score of Tci Gene was 7. The lowest was 4. And the median was 6.


Tci Gene Piotroski F-Score Historical Data

The historical data trend for Tci Gene's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tci Gene Piotroski F-Score Chart

Tci Gene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 7.00 6.00 4.00

Tci Gene Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only 7.00 - 6.00 - 4.00

Competitive Comparison of Tci Gene's Piotroski F-Score

For the Biotechnology subindustry, Tci Gene's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tci Gene's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tci Gene's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Tci Gene's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was NT$11.7 Mil.
Cash Flow from Operations was NT$17.8 Mil.
Revenue was NT$333.9 Mil.
Gross Profit was NT$174.6 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (1163.329 + 1165.94) / 2 = NT$1164.6345 Mil.
Total Assets at the begining of this year (Dec22) was NT$1,163.3 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.0 Mil.
Total Current Assets was NT$1,068.7 Mil.
Total Current Liabilities was NT$155.5 Mil.
Net Income was NT$72.1 Mil.

Revenue was NT$424.0 Mil.
Gross Profit was NT$243.4 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (560.313 + 1163.329) / 2 = NT$861.821 Mil.
Total Assets at the begining of last year (Dec21) was NT$560.3 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.0 Mil.
Total Current Assets was NT$1,076.1 Mil.
Total Current Liabilities was NT$143.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tci Gene's current Net Income (TTM) was 11.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tci Gene's current Cash Flow from Operations (TTM) was 17.8. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=11.673/1163.329
=0.01003413

ROA (Last Year)=Net Income/Total Assets (Dec21)
=72.145/560.313
=0.12875839

Tci Gene's return on assets of this year was 0.01003413. Tci Gene's return on assets of last year was 0.12875839. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Tci Gene's current Net Income (TTM) was 11.7. Tci Gene's current Cash Flow from Operations (TTM) was 17.8. ==> 17.8 > 11.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/1164.6345
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0/861.821
=0

Tci Gene's gearing of this year was 0. Tci Gene's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=1068.72/155.548
=6.87067658

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=1076.053/143.169
=7.51596365

Tci Gene's current ratio of this year was 6.87067658. Tci Gene's current ratio of last year was 7.51596365. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Tci Gene's number of shares in issue this year was 26.482. Tci Gene's number of shares in issue last year was 24.586. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=174.617/333.855
=0.52303245

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=243.359/424.022
=0.57393013

Tci Gene's gross margin of this year was 0.52303245. Tci Gene's gross margin of last year was 0.57393013. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=333.855/1163.329
=0.28698244

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=424.022/560.313
=0.75675917

Tci Gene's asset turnover of this year was 0.28698244. Tci Gene's asset turnover of last year was 0.75675917. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tci Gene has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Tci Gene  (ROCO:6879) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Tci Gene Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Tci Gene's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tci Gene (ROCO:6879) Business Description

Traded in Other Exchanges
N/A
Address
No. 185-1, Gangqian Rd, 10th FLoor, Neihu District, Taipei, TWN
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.

Tci Gene (ROCO:6879) Headlines

No Headlines